18299-1-AP

antibody from Proteintech Group

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

18299-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#18299-1-AP, RRID:AB_2099264

Product name

HER2/ErbB2 antibody

Antibody type

Polyclonal

Description

HER2/ErbB2 antibody (Cat. #18299-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity.

Zhang Z, Xu X, Zhang D, Zhao S, Wang C, Zhang G, Chen W, Liu J, Gong H, Rixiati Y, Li S, Shen T, Li J
Cell metabolism 2024 Mar 5;36(3):541-556.e9

---

Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis.

Yang C, Wang X, To KKW, Cui C, Luo M, Wu S, Huang L, Fu K, Pan C, Liu Z, Fan T, Yang C, Wang F, Fu L
Signal transduction and targeted therapy 2024 Apr 5;9(1):84

---

A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice.

Ma X, Yin J, Qiao L, Wan H, Liu X, Zhou Y, Wu J, Niu L, Wu M, Wang X, Ye H
Molecular cell 2024 Apr 18;84(8):1585-1600.e7

---

Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.

Li W, Zheng C, Xu X, Xia Y, Zhang K, Huang A, Zhang X, Zheng Y, Chen G, Zhang S
Cellular & molecular biology letters 2024 Apr 10;29(1):50

---

A prognostic biomarker NRG1 promotes U-87 MG glioblastoma cell malignancy by inhibiting autophagy via ERBB2/AKT/mTOR pathway.

Lin JZ, Lin N, Zhao WJ
Journal of cellular biochemistry 2023 Sep;124(9):1273-1288

---

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro.

Zhou L, Li C, Zhang R, Li Q, Sun Y, Feng Y, Lan T, Ma J
Virologica Sinica 2023 Oct;38(5):778-786

---

A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.

Hong X, Chen X, Wang H, Xu Q, Xiao K, Zhang Y, Chi Z, Liu Y, Liu G, Li H, Fang J, Lin T, Zhang Y
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Nov;10(32):e2302377

---

Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy.

Xing Y, Zhang F, Ji P, Wei M, Yin C, Yang A, Yang G, Zhao J
Small (Weinheim an der Bergstrasse, Germany) 2023 May;19(20):e2204031

---

Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2.

Cui Y, Wang R, Wei Y, Hou F, Li H, Jiang Y, Sun Y, Fu S, Zuo L, Wang X, Li M, Li J, Liu N, Zhang K, Wei M, Yang G
Bioorganic & medicinal chemistry 2023 Mar 1;81:117202

---

Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study.

Wang H, Cao H, Guo Z
Oncology letters 2023 Jul;26(1):314

---

Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy.

Tuluhong D, Li X, Gao H, Zhu Y, Li Q, Wang S
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2023 Jul 1;32(4):377-387

---

Jatrorrhizine ameliorates Schwann cell myelination via inhibiting HDAC3 ability to recruit Atxn2l for regulating the NRG1-ErbB2-PI3K-AKT pathway in diabetic peripheral neuropathy mice.

Gong X, Gui Z, Ye X, Li X
Phytotherapy research : PTR 2023 Feb;37(2):645-657

---

Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer.

Peippo M, Gardberg M, Kronqvist P, Carpén O, Heuser VD
Journal of breast cancer 2023 Dec;26(6):525-543

---

EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.

Lv D, Zhong C, Dixit D, Yang K, Wu Q, Godugu B, Prager BC, Zhao G, Wang X, Xie Q, Bao S, He C, Heiland DH, Rosenfeld MG, Rich JN
Molecular cell 2023 Dec 7;83(23):4334-4351.e7

---

Squalene epoxidase promotes breast cancer progression by regulating CCNB1 protein stability.

Tuluhong D, Gao H, Li X, Wang L, Zhu Y, Xu C, Wang J, Li H, Li Q, Wang S
Experimental cell research 2023 Dec 1;433(1):113805

---

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression.

Bi J, Wu Z, Zhang X, Zeng T, Dai W, Qiu N, Xu M, Qiao Y, Ke L, Zhao J, Cao X, Lin Q, Chen XL, Xie L, Ouyang Z, Guo J, Zheng L, Ma C, Guo S, Chen K, Mo W, Fu G, Zhao TJ, Wang HR
Nature communications 2023 Apr 24;14(1):2342

---

Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells.

Adediran S, Wang L, Khan MA, Guang W, Fan X, Dan H, Qi J, Jay SM, Carrier F, Hussain A
Cancers 2022 Sep 23;14(19)

---

Label-Free Plasmon-Enhanced Spectroscopic HER2 Detection for Dynamic Therapeutic Surveillance of Breast Cancer.

Xie Y, Wen Y, Su X, Zheng C, Li M
Analytical chemistry 2022 Sep 20;94(37):12762-12771

---

Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience.

Bai X, He W, Yin H, Li X, Zhou X, Wei Z, Yu H, Gou X
Experimental and therapeutic medicine 2022 Nov;24(5):704

---

Moderate heart rate reduction promotes cardiac regeneration through stimulation of the metabolic pattern switch.

Tan J, Yang M, Wang H, Shen C, Wu M, Xu H, Wu Y, Li Y, Li X, Huang T, Deng S, Yang Z, Gao S, Li H, Zhou J, Chen H, Cao N, Cai W
Cell reports 2022 Mar 8;38(10):110468

---

Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.

Hu T, Liu Y, Wu J, Hu XL, Zhao G, Liang B, Wang S, Long M
Journal of clinical medicine 2022 Mar 14;11(6)

---

Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Zhao S, Wang Y, Yang N, Mu M, Wu Z, Li H, Tang X, Zhong K, Zhang Z, Huang C, Cao T, Zheng M, Wang G, Nie C, Yang H, Guo G, Zhou L, Zheng X, Tong A
Journal for immunotherapy of cancer 2022 Jun;10(6)

---

Fast detection, a precise and sensitive diagnostic agent for breast cancer.

Wu Q, Yuan C, Liu N, Shu J, Wang J, Qian J, Zeng L, Zhang H, Wang X, Mei W
Journal of experimental & clinical cancer research : CR 2022 Jun 13;41(1):201

---

Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.

Khayeka-Wandabwa C, Zhao J, Pathak JL, Wu H, Bureik M
Breast cancer research and treatment 2022 Jan;191(2):319-326

---

Ionic Liquid-Based Extraction System for In-Depth Analysis of Membrane Protein Complexes.

Chu H, Zhao Q, Liu J, Yang K, Wang Y, Liu J, Zhang K, Zhao B, He H, Zheng Y, Zhong S, Liang Z, Zhang L, Zhang Y
Analytical chemistry 2022 Jan 18;94(2):758-767

---

Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology.

Lai J, Jiang F, Zhuo X, Xu X, Liu L, Yin K, Wang J, Zhao J, Xu W, Liu H, Wang X, Jiang W, Wang K, Yang S, Guo H, Qi F, Yuan X, Lin X, Fu G
Chinese medicine 2022 Dec 17;17(1):140

---

FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.

Zhao F, Ge F, Xie M, Li Z, Zang C, Kong L, Pu Y, Zheng X, Tan Y
Clinical & experimental metastasis 2022 Aug;39(4):623-639

---

Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.

Wang J, Huang Q, Hu X, Zhang S, Jiang Y, Yao G, Hu K, Xu X, Liang B, Wu Q, Ma Z, Wang Y, Wang C, Wu Z, Rong X, Liao W, Shi M
Cancer research 2022 Apr 15;82(8):1503-1517

---

Rolling Circle Amplification-Assisted Flow Cytometry Approach for Simultaneous Profiling of Exosomal Surface Proteins.

Gao X, Teng X, Dai Y, Li J
ACS sensors 2021 Oct 22;6(10):3611-3620

---

PET-CT and RNA sequencing reveal novel targets for acupuncture-induced lowering of blood pressure in spontaneously hypertensive rats.

Li J, Peng C, Lai D, Fang Y, Luo D, Zhou Z, Li C, Lai X
Scientific reports 2021 May 26;11(1):10973

---

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.

Li H, Wang J, Yi Z, Li C, Wang H, Zhang J, Wang T, Nan P, Lin F, Xu D, Qian H, Ma F
European journal of cancer (Oxford, England : 1990) 2021 Mar;145:92-108

---

MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2.

Xu Y, Zhang L, Xia L, Zhu X
Oncology letters 2021 Jun;21(6):457

---

Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.

Jiao X, Wang B, Feng C, Song S, Tian B, Zhou C, Gao X, Sun W, Liu P
BMC cancer 2021 Jun 30;21(1):760

---

NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells.

Liu WJ, Huang YX, Wang W, Zhang Y, Liu BJ, Qiu JG, Jiang BH, Liu LZ
Cells 2021 Jun 30;10(7)

---

HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.

Takahashi K, Taki S, Yasui H, Nishinaga Y, Isobe Y, Matsui T, Shimizu M, Koike C, Sato K
Cancer medicine 2021 Dec;10(24):8808-8819

---

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features.

Mei Y, Cai D, Dai X
Journal of Cancer 2020;11(5):1162-1169

---

Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.

Pu X, Zhu L, Li F, Zheng J, Wu H, Fu Y, Chen J, Qi L
Pathology, research and practice 2020 Sep;216(9):153116

---

Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy.

Tan Y, Peng Y, Ai L, Li Y, Qu YX, Wang D, Su Y, Deng T, Fu T, Zhao Z, Wang XQ, Tan W
Bioconjugate chemistry 2020 Jul 15;31(7):1766-1774

---

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.

Yang ZY, Yang L, Xu CW, Wang XJ, Lei L
Biology open 2020 Jan 24;9(1)

---

CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.

Xiang R, Han X, Ding K, Wu Z
Pathology, research and practice 2020 Feb;216(2):152776

---

BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway.

Lin L, Luo X, Wang L, Xu F, He Y, Wang Q, Yuan C, Xu J, Yan L, Hao H
International immunopharmacology 2020 Aug;85:106625

---

SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.

Liu R, Shuai Y, Luo J, Zhang Z
Frontiers in oncology 2019;9:1035

---

Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes.

Jiang L, Jiang T, Luo J, Kang Y, Tong Y, Song X, Gao X, Yao W, Tian H
Journal of immunology research 2019;2019:7914326

---

FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6.

Dai X, Cheng H, Chen X, Li T, Zhang J, Jin G, Cai D, Huang Z
International journal of biological sciences 2019;15(5):1030-1041

---

ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control.

Dai X, Mei Y, Chen X, Cai D
Frontiers in genetics 2019;10:790

---

Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.

Wang D, Hu X, Liu C, Jia Y, Bai Y, Cai C, Wang J, Bai L, Yang R, Lin C, Liu YR, Li S, Qiao F, Yao L, Chen L, Ge G, Jiang H, Li D, Li L, Chen J, Shao ZM, Zeng YA
Cell research 2019 Oct;29(10):832-845

---

Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.

Namba M, Hattori N, Hamada H, Yamaguchi K, Okamoto Y, Nakashima T, Masuda T, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Kohno N
Cancer letters 2019 Feb 1;442:31-39

---

The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.

Zheng X, Chen Y, Bai M, Liu Y, Xu B, Sun R, Zeng H
Free radical biology & medicine 2019 Feb 1;131:7-17

---

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X, He X, Zhang X
Nature communications 2018 Nov 9;9(1):4718

---

Protein C receptor stimulates multiple signaling pathways in breast cancer cells.

Wang D, Liu C, Wang J, Jia Y, Hu X, Jiang H, Shao ZM, Zeng YA
The Journal of biological chemistry 2018 Jan 26;293(4):1413-1424

---

Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.

Li Y, Li L, Zhang G, Wang Y, Chen H, Kong R, Pan S, Sun B
Investigational new drugs 2018 Feb;36(1):20-27

---

Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.

Li G, Zheng J, Xu B, Ling J, Qiu W, Wang Y
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017 Jan;85:418-424

---

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.

Zhang WJ, Li Y, Wei MN, Chen Y, Qiu JG, Jiang QW, Yang Y, Zheng DW, Qin WM, Huang JR, Wang K, Zhang WJ, Wang YJ, Yang DH, Chen ZS, Shi Z
Cancer letters 2017 Feb 1;386:100-109

---

Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Tan S, Ding K, Chong QY, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W, Zhang M, Li G, Li X, Kong X, Ahmad A, Wu Z, Wu Q, Zhao X, Lobie PE, Zhu T
The Journal of biological chemistry 2017 Aug 18;292(33):13551-13564

---

Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.

Zhang Z, Li HM, Zhou C, Li Q, Ma L, Zhang Z, Sun Y, Wang L, Zhang X, Zhu B, Hong YS, Wu CZ, Liu H
Journal of experimental & clinical cancer research : CR 2016 Sep 22;35(1):149

---

Novel method to rescue a lethal phenotype through integration of target gene onto the X-chromosome.

Sakata K, Araki K, Nakano H, Nishina T, Komazawa-Sakon S, Murai S, Lee GE, Hashimoto D, Suzuki C, Uchiyama Y, Notohara K, Gukovskaya AS, Gukovsky I, Yamamura KI, Baba H, Ohmuraya M
Scientific reports 2016 Nov 15;6:37200

---

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.

Lu Y, Wang Y, Zhang M, Liu L, Li F, Zhang J, Ye M, Zhao H, Zhao J, Yan B, Yang A, Zhang R, Li X, Ren X
Oncotarget 2016 Apr 26;7(17):23594-607

---

Cellular stress induces cap-independent alpha-enolase/MBP-1 translation.

Maranto C, Perconti G, Contino F, Rubino P, Feo S, Giallongo A
FEBS letters 2015 Jul 22;589(16):2110-6

---

Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.

Contino F, Mazzarella C, Ferro A, Lo Presti M, Roz E, Lupo C, Perconti G, Giallongo A, Feo S
BMC cancer 2013 Feb 19;13:81

---

Effect of acute acid-base disturbances on ErbB1/2 tyrosine phosphorylation in rabbit renal proximal tubules.

Skelton LA, Boron WF
American journal of physiology. Renal physiology 2013 Dec 15;305(12):F1747-64

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

HeLa cells were subjected to SDS PAGE followed by western blot with 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:2000

Sample type

cell line

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human breast cancer using 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:50 (under 10x lens)

Sample type

tissue

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human breast cancer using 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:50 (under 40x lens)

Sample type

tissue

Flow cytometry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The HER2/ErbB2 antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human HER2/ErbB2. This antibody recognizes human,mouse,rat antigen. The HER2/ErbB2 antibody has been validated for the following applications: ELISA, WB, IHC, FC analysis.

Appendix

18299-1-AP.pdf

Show more